IDEAYA Biosciences公司宣布，已签署一项临床合作协议，旨在评估其研发的候选药物Ide849与阿斯利康的Imfinzi（度伐利尤单抗）联合疗法，用于治疗广泛期小细胞肺癌（ES-SCLC）患者。
该研究将探索这种联合疗法的安全性、耐受性及初步疗效，为后续的临床开发提供关键数据依据。广泛期小细胞肺癌是一种侵袭性强、治疗选择有限的恶性肿瘤，此项合作有望为该患者群体带来新的治疗希望。
IDEAYA Biosciences公司宣布，已签署一项临床合作协议，旨在评估其研发的候选药物Ide849与阿斯利康的Imfinzi（度伐利尤单抗）联合疗法，用于治疗广泛期小细胞肺癌（ES-SCLC）患者。
该研究将探索这种联合疗法的安全性、耐受性及初步疗效，为后续的临床开发提供关键数据依据。广泛期小细胞肺癌是一种侵袭性强、治疗选择有限的恶性肿瘤，此项合作有望为该患者群体带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.